Market Overview:
The global dysplasia epiphysealis hemimelica treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of dysplasia epiphysealis hemimelica, rising awareness about the disease, and technological advancements in the field of orthopedics. However, factors such as high cost of treatment and lack of reimbursement policies are restraining the growth of this market. The hip replacement surgery segment is expected to dominate the global dysplasia epiphysealis hemimelica treatment market during the forecast period owing to its high efficacy in treating dysplasia epiphysealis hemimelica. The knee replacement surgery segment is projected to grow at a higher CAGR than other segments during the forecast period owing to increasing prevalence of osteoarthritis, which leads to development Dysplasia Epiphysealis Hemimelica (DEH).
Product Definition:
Dysplasia epiphysealis hemimelica (DEH) is a rare disorder that results in the abnormal development of one half of the hip bone. Symptoms include pain and stiffness in the hip, difficulty walking, and a decrease in range of motion. DEH is treated with surgery to remove the affected portion of the hip bone.
Hip Replacement Surgery:
Hip replacement surgery is a surgical procedure used to restore the hip joint and enable pain-free movement of the legs. The most common cause of hip degeneration is obesity, which leads to muscle imbalance in the body. As weight increases on the pelvis, it changes pressure points causing pain and eventually lead to hip problems.
Knee Replacement Surgery:
Knee replacement surgery is a surgical procedure used to restore knee joint function by replacing damaged cartilage and bone with an artificial implant. The most common cause of knee pain in adults is arthritis, which usually affects the older population. Knee replacement surgeries are performed on patients suffering from severe osteoarthritis, rheumatoid arthritis or trauma who have become unable to walk due to severe pain.
Application Insights:
The others segment held the largest share of the global market in 2017. This can be attributed to growing awareness about various treatment options for dysplasia epiphysealis hemimelica and increasing availability of advanced healthcare facilities. The hospital segment is expected to grow at a lucrative rate during the forecast period owing to rising prevalence of diseases such as osteoarthritis and rheumatoid arthritis, which leads to high demand for knee replacement surgeries. According to WHO, around 60-80% people suffer from joint pain at some point in their life due to wear & tear caused by excessive use or improper maintenance of joints over a period. Thus, increasing number of patients suffering from joint pain is anticipated fuel market growth during the forecast period.
Knee replacement surgery is one among several surgical treatments available for OA (osteoarthritis).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to increasing prevalence of osteoarthritis, rising preference for minimally invasive surgeries, and availability of highly advanced healthcare infrastructure. In addition, favorable reimbursement policies are further expected to propel the regional growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to growing geriatric population and improving economic conditions in emerging countries such as China and India. Moreover, rapidly developing medical tourism industry will also boost this region’s growth prospects during the estimated time span.
Growth Factors:
- Increasing incidence of dysplasia epiphysealis hemimelica (DEH)
- Growing awareness about DEH and its treatment options
- Rising demand for better and more effective treatments for DEH
- Availability of new and innovative therapies for DEH treatment
- Growing number of research studies on DEH
Scope Of The Report
Report Attributes
Report Details
Report Title
Dysplasia Epiphysealis Hemimelica Treatment Market Research Report
By Type
Hip Replacement Surgery, Knee Replacement Surgery, Surgical Excision of Mass with Preservation of the Joint
By Application
Hospital, Ambulatory Surgical Center, Others
By Companies
Zimmer Biomet, AstraZeneca, Genentech, Pfizer, Johnson&Johnson, Novartis, Teva, Medacta
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
144
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Dysplasia Epiphysealis Hemimelica Treatment Market Report Segments:
The global Dysplasia Epiphysealis Hemimelica Treatment market is segmented on the basis of:
Types
Hip Replacement Surgery, Knee Replacement Surgery, Surgical Excision of Mass with Preservation of the Joint
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Ambulatory Surgical Center, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Zimmer Biomet
- AstraZeneca
- Genentech
- Pfizer
- Johnson&Johnson
- Novartis
- Teva
- Medacta
Highlights of The Dysplasia Epiphysealis Hemimelica Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hip Replacement Surgery
- Knee Replacement Surgery
- Surgical Excision of Mass with Preservation of the Joint
- By Application:
- Hospital
- Ambulatory Surgical Center
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dysplasia Epiphysealis Hemimelica Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dysplasia Epiphysealis Hemimelica is a rare disorder that affects the skin and nails. It causes abnormal growth of the epidermis (the outer layer of the skin) and dermis (the layer beneath the skin). This can lead to thick, hard patches on the skin called hemimelia. The nails may also be affected, becoming thin, brittle, and discolored. Dysplasia Epiphysealis Hemimelica treatment typically includes surgery to remove these abnormalities.
Some of the major companies in the dysplasia epiphysealis hemimelica treatment market are Zimmer Biomet, AstraZeneca, Genentech, Pfizer, Johnson&Johnson, Novartis, Teva, Medacta.
The dysplasia epiphysealis hemimelica treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dysplasia Epiphysealis Hemimelica Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dysplasia Epiphysealis Hemimelica Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dysplasia Epiphysealis Hemimelica Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dysplasia Epiphysealis Hemimelica Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dysplasia Epiphysealis Hemimelica Treatment Market Size & Forecast, 2018-2028
4.5.1 Dysplasia Epiphysealis Hemimelica Treatment Market Size and Y-o-Y Growth
4.5.2 Dysplasia Epiphysealis Hemimelica Treatment Market Absolute $ Opportunity
Chapter 5 Global Dysplasia Epiphysealis Hemimelica Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Type
5.2.1 Hip Replacement Surgery
5.2.2 Knee Replacement Surgery
5.2.3 Surgical Excision of Mass with Preservation of the Joint
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dysplasia Epiphysealis Hemimelica Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Ambulatory Surgical Center
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dysplasia Epiphysealis Hemimelica Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dysplasia Epiphysealis Hemimelica Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Type
9.6.1 Hip Replacement Surgery
9.6.2 Knee Replacement Surgery
9.6.3 Surgical Excision of Mass with Preservation of the Joint
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Ambulatory Surgical Center
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dysplasia Epiphysealis Hemimelica Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Type
10.6.1 Hip Replacement Surgery
10.6.2 Knee Replacement Surgery
10.6.3 Surgical Excision of Mass with Preservation of the Joint
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Ambulatory Surgical Center
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dysplasia Epiphysealis Hemimelica Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Type
11.6.1 Hip Replacement Surgery
11.6.2 Knee Replacement Surgery
11.6.3 Surgical Excision of Mass with Preservation of the Joint
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Ambulatory Surgical Center
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dysplasia Epiphysealis Hemimelica Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Type
12.6.1 Hip Replacement Surgery
12.6.2 Knee Replacement Surgery
12.6.3 Surgical Excision of Mass with Preservation of the Joint
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Ambulatory Surgical Center
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dysplasia Epiphysealis Hemimelica Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Type
13.6.1 Hip Replacement Surgery
13.6.2 Knee Replacement Surgery
13.6.3 Surgical Excision of Mass with Preservation of the Joint
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dysplasia Epiphysealis Hemimelica Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Ambulatory Surgical Center
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dysplasia Epiphysealis Hemimelica Treatment Market: Competitive Dashboard
14.2 Global Dysplasia Epiphysealis Hemimelica Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Zimmer Biomet
14.3.2 AstraZeneca
14.3.3 Genentech
14.3.4 Pfizer
14.3.5 Johnson&Johnson
14.3.6 Novartis
14.3.7 Teva
14.3.8 Medacta
